{"id":385,"date":"2018-01-02T21:41:55","date_gmt":"2018-01-02T20:41:55","guid":{"rendered":"https:\/\/10storks.com\/?p=385"},"modified":"2018-01-02T21:41:55","modified_gmt":"2018-01-02T20:41:55","slug":"cbr-cord-blood-registry","status":"publish","type":"post","link":"https:\/\/imedicalsociety.org\/cbr-cord-blood-registry\/","title":{"rendered":"CBR Cord Blood Registry"},"content":{"rendered":"

[vc_row][vc_column][td_block_3 limit=”6″ header_color=”#a931d8″ td_ajax_filter_type=”” ajax_pagination=”next_prev”][\/vc_column][\/vc_row]<\/h1>\n

CBR Cord Blood Registry<\/h1>\n

CBR Systems Incorporated (Cord Blood Registry) is a biotechnology company in the field of stem cells<\/a> banking with more than 20 years of experience in this specific area.\u00a0 Along with the service of banking stem cells<\/a>, Cord Blood Registry funds clinical trials focused on the research and development of new therapeutic modalities that include stem cells application<\/a>, what is also the case for ViaCord<\/a>, Maze,<\/a> FamilyCord<\/a> and others.<\/a> This organization, as a cord blood registry, strives to find a cure for severe conditions that cannot be appropriately managed today, despite the many cord blood uses<\/a> available, and aims to find possibilities and solutions for families and their members who suffer from potentially life-threatening diseases.<\/p>\n

This company, Cord Blood Registry is one of the many companies reviewed in this article<\/a>, in comparison to some of its competitors, such as StemCyte.<\/a><\/p>\n

Cord Blood Registry stores approximately a half of the overall number of stem cell units in the country, being one of the most important cord blood banks in the United States<\/a>.<\/p>\n

CBR Cord Blood Registry<\/figcaption><\/figure>\n

 <\/p>\n

Sometimes called as body \u201dmaster cells\u201d, stem cells<\/a> have the potential to develop differentiated tissues such as blood, brain, bone and numerous other body organs.\u00a0 Use of baby stem cells<\/a> in the treatment of various, today incurable diseases is still in its beginning, but the results are promising.\u00a0 Adequate and professional approach to this therapeutic modality is an important prerequisite for a safe and effective treatment outcome. Currently, the only indication approved for the use of stem cells<\/a> by the United States Food and Drug Administration (FDA)<\/a> is the hematopoietic stem cell transplantation focused to cure disorders of the blood and immune system.\u00a0 However, there is a variety of clinical trials going on, aimed to broaden the indication field of stem cell therapy<\/a>.<\/p>\n

Cord Blood and Cord Tissue Collection Kit<\/h2>\n

Cord Blood Registry<\/a> developed a unique unit collection kit<\/a>, which was designed specifically to be safe and ensure the maximal sample quality for cord tissue<\/a> and cord blood.\u00a0 By using this specific collection kit, the cord blood collection is completely safe and painless for the baby.\u00a0 Additionally, the kit design allows that the delivery process does not need to be changed in any way in order to improve the quality of cord blood unit.\u00a0 Furthermore, Cord Blood Registry issued a specific program called Healthcare Provider Network (HPN) in order to educate the healthcare providers that are responsible for cord blood collection to ensure the effectiveness and safety of the procedure.\u00a0 Moreover, HPN seeks to offer tools for healthcare professionals to collect samples with sufficient quality to be used in future medical practice and ensures that a proper feedback regarding the quality of samples<\/a> is given to the family.<\/p>\n

Therefore, and as in the case of ViaCord<\/a>, or also Carolina,<\/a> more than one sample is stored for each umbilical cord.<\/p>\n

 <\/p>\n

Stem Cell Research and Clinical Trials<\/h2>\n

 <\/p>\n

Cord Blood Registry, or CBR,<\/a>\u00a0 actively supports the conduct of FDA-regulated clinical trials<\/a> involving stem cell therapies.\u00a0 Researchers hope to ultimately fully understand and establish the regular use of stem cell therapy in the management of acquired hearing loss, autism, cerebral palsy and pediatric stroke.<\/p>\n